Journal of Modern Techniques in Biology and Allied Sciences
This Content Available at www.lapinjournals.com ISSN (O): 3048-9970
(An International online peer reviewed Journal)

Review Article Open Access

PRACTICAL IMPLEMENTATION OF ONCOLYTIC VIRUS THERAPY IN THE HOSPITAL: SAFETY PROTOCOLS AND OPERATIONAL GUIDELINES

Pritam Pawara[1,6], Bhagwati Ram[2], Vaishnavi Bandewar[3], Harshjeet A. Sisode[4], Harshada Pawara[5], Ansari Imtiyaz Ejaz[6]

[1]R. C. Patel Institute of Pharmacy, Shirpur, Maharashtra, India
[2]Mvm institute of nursing science Affiliation by Rajiv Gandhi University of health sciences
[3]Rajputana college of pharmacy, Karnataka, India
[4]KVPS Institute of pharmaceutical education and research Boradi,Shirpur, Maharashtra, India
[5]DCS's ARA College of Pharmacy, Nagaon, Dhule, Maharashtra
[6]R.C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Dist. Dhule, Maharashtra.

Article History: Received: 14 July, 2025, Revised: 22 Aug, 2025, Accepted: 16 Sept, 2025, Published: 30 Sept, 2025

*Corresponding author
Ansari Imtiyaz Ejaz

DOI: https://doi.org/10.70604/jmtbas.v2i3.96

Abstract

The integration of oncolytic virus (OV) therapies into clinical practice introduces unique challenges for hospitals and healthcare teams. Unlike conventional cancer drugs, OVs are live replicating viruses, requiring special handling, storage, and safety precautions. This article reviews key operational considerations for safely implementing oncolytic virotherapy in a hospital setting. Topics include biosafety protocols (classification of OVs as BioSafety Level 2 agents, personal protective equipment, and staff training), cold-chain logistics (ultra-low temperature storage and thawing procedures), preparation and administration guidelines (compounding live virus doses in pharmacy cleanrooms and intratumoral injection techniques), and containment measures to prevent unintended exposure or viral shedding to healthcare workers and patients' contacts. We discuss the development of standard operating procedures (SOPs) and the importance of interdisciplinary coordination among pharmacy, nursing, infection control, and clinical teams. Practical steps – from handling biohazardous waste to patient counseling on post-treatment precautions – are outlined. By establishing robust protocols and training programs, hospitals can safely deliver these novel therapies. This review provides a framework for institutions to navigate the logistical and safety aspects of oncolytic virotherapy, ensuring maximal benefit to patients while protecting staff and the public.

Keywords: Oncolytic virotherapy; Hospital implementation; Biosafety; Cold chain; Viral shedding; Standard operating procedures; Pharmacy; Infection control; Intratumoral injection

Introduction

The emergence of oncolytic virus therapies (e.g., T-VEC for melanoma) has prompted hospitals to develop new protocols for handling and administering these agents [1]. T-VEC is the prototypical HSV-1 oncolytic virus, and its development builds on advances in the growth, purification, and titration of HSV vectors that have been standardized for both research and clinical translation [2]. Oncolytic viruses (OVs) offer a promising modality by selectively infecting and killing cancer cells, but their use in clinical practice comes with operational challenges distinct from those of conventional chemotherapy or monoclonal antibodies [3]. In essence, OVs can transform an immunologically 'cold' tumor (one that evades immune recognition) into a 'hot' tumor (an inflamed site teeming with immune activity), a principle consistent with recent insights into T-cell and NK-cell immune evasion in solid tumors [4]. Additionally, virus-induced tumor cell death is often highly immunogenic: unlike the apoptosis seen with many chemotherapies (which can be immunologically quiet), virus-mediated lysis releases a profusion of immunostimulatory molecules. This is mechanistically aligned with studies showing that disrupting DNA repair checkpoints and inducing replication stress enhances

tumor immunogenicity [5]. Because OVs are live, replication-competent viruses, healthcare institutions must treat them with precautions akin to a hybrid of cytotoxic drugs and infectious pathogens. Safe implementation of oncolytic virotherapy requires careful planning encompassing pharmacy preparation, nursing administration, patient management, and environmental safety [6,7].

This article explores practical aspects of integrating oncolytic virus treatments into a hospital setting. We outline the necessary biosafety measures, specialized storage and handling procedures, and multidisciplinary training that enable these therapies to be delivered safely. We also address managing viral shedding and waste disposal and describe the development of standard operating procedures (SOPs) tailored to OVs. By sharing early institutional experiences and guidelines, we aim to provide a roadmap for centers preparing to offer oncolytic virotherapy to their patients.

Biosafety and Handling Requirements

Oncolytic viruses are typically handled under Biosafety Level 2 (BSL-2) precautions, reflecting their status as agents that can pose moderate risk to personnel and the environment if mishandled. Practically, BSL-2 designation means enforcing specific safety measures whenever an OV is stored, prepared, administered, or disposed [8]:

Controlled Access and Trained Personnel: Only designated, trained personnel should be involved in OV handling and patient care. Many institutions restrict involvement to oncology pharmacy and nursing staff who have completed specialized training in handling biohazardous drugs. Staffs who are pregnant or immunocompromised (or otherwise at higher risk) are generally excused from direct contact as a precaution [9, 10].

Personal Protective Equipment (PPE):

When preparing or administering an OV, healthcare workers wear protective gear similar to that for chemotherapy and infectious agents. This includes a disposable gown, nitrile gloves (often doubled), eye protection, and sometimes an N95 mask or face shield if there is a risk of aerosol generation. During intratumoral injection procedures, splash protection is crucial because the injection can cause minor bleeding or leakage of tumor fluid [11–13].

Biological Safety Cabinet (BSC)

All OV dose preparation is performed in a Class II biological safety cabinet (vertical laminar-flow hood with HEPA filtration) in the pharmacy cleanroom. The BSC provides containment, protecting the compounder and environment from accidental exposure. Some pharmacies use a BSC with negative pressure or a closed isolator for hazardous biologics [14–17]. After compounding an OV, the BSC interior surfaces are thoroughly decontaminated with a virucidal disinfectant (such as bleach or peracetic acid), and the cabinet is purged for a period of time (e.g., 30–60 minutes) before the next use. Some centers schedule OV compounding as the first task of the day in the cleanroom to allow ample time for cleaning and to avoid overlapping with routine chemo preparations [18,19].

Spill and Exposure Management:

Pharmacy and nursing teams must have clear plans for accidental spills or exposures. A specialized spill kit for oncolytic viruses is kept in areas where the OV is prepared or administered. These kits include absorbent materials, disposable towels, gloves, and a virucidal agent (bleach solution is commonly recommended) to inactivate any spillage. If a spill occurs inside the BSC, the compounder (in full PPE) contains and disinfects it per protocol. For spills outside a cabinet (e.g., in a patient room), the area is isolated and cleaned with virucide by trained staff. Sharps (needles) involved in OV handling are disposed of immediately in puncture-proof biohazard sharps containers. In case of personnel exposure – such as a needle stick or a splash to skin/eyes – the protocol is immediate washing of the area and notification of occupational health/infection control. Medical evaluation and possible antiviral prophylaxis (depending on the virus) may be considered, although to date serious exposures have been exceedingly rare. Notably, for viruses like HSV (T-VEC) or adenovirus, effective antivirals (e.g., acyclovir) exist if needed [20–22], (Additional biosafety measures, such as rigorous labeling of OV materials with biohazard symbols and posting signage when an OV is in use, are also employed to alert all staff to the presence of a live virus.)

Cold-Chain Storage and Preparation

Many oncolytic viruses require ultra-cold storage. Products are often shipped and stored at –80°C to –60°C. For example, T-VEC is supplied on dry ice and kept in a –70°C freezer until use. Hospital pharmacies must have appropriate freezer capacity or arrange just-in-time delivery of doses. Inventory management is crucial: vials may come in different sizes (T-VEC has multiple vial strengths), and pharmacists plan to have the right vial combinations on hand to make up the prescribed dose without wastage [23].

On the day of treatment, the pharmacy retrieves the OV vial from the freezer and thaws it immediately before preparation. Thawing is done quickly (e.g., by hand warming or at room temperature for a few minutes) per product instructions. Once thawed, the virus solution must not be refrozen. A pharmacist or trained technician then draws up the required dose into syringes within the BSC, using sterile technique. Often, one syringe is prepared for each injection site (lesion) to be treated. Any excess virus that cannot be used must be discarded; hence doses are drawn up as exactly as possible to the ordered amount [24, 25].

After preparation, all materials that contacted the virus – needles, syringes, vials, gloves, etc. – are treated as

biohazardous waste. Used sharps go into biohazard sharps containers, and other disposable items into red biohazard bags. These are later autoclaved or incinerated according to hospital policy for infectious waste [26]. The pharmacy staff also disinfects the outside of each filled syringe (with a virucidal wipe) and then places the syringe in a sealed plastic bag or secondary container for transport to the patient, preventing any drips during transit [27].

Because OV doses are time-sensitive (live virus can lose potency), coordination is important. The pharmacy typically pages the treatment team when leaving to deliver the dose, so that the patient is ready upon syringe arrival. If any delay occurs, the syringe is kept cold (e.g., in a refrigerator or cooler, depending on stability data) until it can be administered [23].

Administration and Patient Management

Oncolytic virus therapy is usually administered by a physician in a clinic or procedure room. The pharmacy delivers the prepared syringe(s) to the treatment area in a cooler or protective container labeled as biohazard. Intratumoral injection is the typical route: the physician injects the OV directly into one or more tumor lesions (for deep tumors, often under ultrasound or CT guidance; for superficial tumors, by direct visualization) [28–30].

During the injection procedure, precautions are taken to prevent viral escape:

- The injection site and surrounding area are prepared and isolated with drapes. As soon as the needle is withdrawn, the site is covered with sterile gauze and then sealed with an occlusive dressing (often a transparent film) to contain any virus that might leak from the tumor. These dressings are kept on for at least several days. For T-VEC, patients are instructed to keep sites covered for 7 days (or until any oozing stops) and to change dressings using gloves [31].
- All needles and supplies used are immediately placed into biohazard receptacles. The treating team (physician and assisting nurse) wear PPE (gown, gloves, eye protection) during the procedure. After administration, any surfaces or reusable equipment (e.g., an ultrasound probe, procedure table) that may have meet the virus are cleaned with a virucidal disinfectant. Environmental services may perform a terminal cleaning of the room if needed, though in many cases standard cleaning with appropriate agents suffices [32].

  If the patient is being treated as outpatient, they are typically observed briefly after injection (to ensure no immediate reaction or complications) and then allowed to go home with detailed instructions. In the less common scenario of an inpatient receiving OV therapy, the patient might be placed on contact precautions for a short period post-injection. This could include the use of gloves and gowns by anyone entering the room and dedicated equipment, similar to precautions for patients with certain infections. Such measures are individualized based on the virus and extent of shedding expected [33–35].

  Managing viral shedding is an important aspect of patient management. Depending on the virus and route, OVs can be present in bodily fluids for days to weeks. For example, reovirus has been detected in stool and respiratory secretions for about a week post-infusion. HSV from T-VEC could potentially shed from injection site secretions or herpetic lesions if they occur. Patients are given specific home instructions to minimize the risk of exposing others: for instance, avoid close physical contact (especially kissing or sexual contact) for a few days if lesions are in areas that could transmit virus, use condoms for about a week after treatment, and avoid public swimming pools or hot tubs shortly after treatment (to prevent the unlikely scenario of virus entering the water). In practice, significant transmission of oncolytic viruses to third parties has not been reported, likely due to the containment measures and the fact that these viruses are attenuated. Nonetheless, these precautions add a layer of safety and reassurance [36].

  Pharmacists and nurses also counsel patients on what side effects to expect and how to manage them. Flu-like symptoms (fever, chills, fatigue) are common, typically lasting 24–48 hours after injection. Patients are advised that they may take acetaminophen or NSAIDs at home to relieve fever or aches, and to stay well hydrated and rest. Injection site pain or inflammation is also expected – they can use cold packs, topical ointments, or over-the-counter pain relievers as needed. Importantly, patients are taught the difference between expected inflammation and signs of complication (like severe pain with high fever, which could indicate an abscess or infection requiring medical attention). In the case of HSV-based OVs like T-VEC, patients are warned about the possibility (though low) of herpetic lesions developing on the skin. They are instructed to report any new rash or blister, and the care team may have an antiviral medication ready just in case. By setting these expectations and providing contact information for the clinic, patients are empowered to manage mild effects at home and to know when to call for help [37].

Developing SOPs and Staff Training

- Launching oncolytic virus therapy at an institution requires clear Standard Operating Procedures (SOPs). The pharmacy department usually takes the lead in drafting these, in collaboration with nursing, infection control, and other stakeholders. A comprehensive OV SOP covers the entire process: from ordering and receiving receipt, through storage, preparation, administration, and post-treatment precautions(38). Key elements include:

- **Receipt & Storage**
  Detailed steps for logging the OV into inventory and storing it at the correct temperature immediately upon arrival. Often only pharmacy supervisors or designated pharmacists have access to ultra-cold storage to maintain chain-of-custody (especially as some OVs are investigational or high-value).
- **Dose Verification**
  Instructions for pharmacists to verify the dose and volume based on the treatment protocol. For example, if dosing is lesion-size dependent (as with T-VEC), the SOP might require pharmacy to double-check the lesion measurements and prescribed volume for each lesion.
- **Compounding Procedure**
  Step-by-step directions for thawing the vial, drawing up the dose in the BSC (including what syringes and needles to use), labeling syringes (often each syringe is labeled for a specific lesion or with "Virus – Do Not Shake" warnings), and packaging for transport (using sealed bags, etc.). It also outlines required PPE and the disinfection steps afterward.
- **Administration Protocol**
  Guidelines for the clinical team on how to handle the patient. This may mean that two staff members (e.g., doctor and nurse) should be present, that they should wear PPE, and how to apply dressings post-injection. It would also cover any required observation time after injection and any vital sign monitoring.
- **Waste Disposal & Decontamination**
  Clear instructions on handling waste and cleaning. For example: "Place all used items in double red bags; seal and dispose via incineration. Clean any spills with 10% bleach. In case of skin exposure, do X, Y, Z..." etc.

Once the SOP is approved, training is conducted. Pharmacy staff who will handle the OV receive hands-on training in the preparation steps (sometimes practicing with a dummy vial or similar). Oncology nurses and any physicians administering the virus are also educated on the SOP. Often, a multidisciplinary in-service is held so everyone understands each other's roles. For example, the nurse learns how the pharmacy will deliver the syringe and what to do with it, the pharmacist learns how the physician plans to inject and what assistance they might need, and infection control reviews the steps to ensure compliance [39,40].

Training includes emergency scenarios too – like how to respond if a vial is dropped and broken, or if a patient vomits (if an OV were given IV). These scenarios are rare but having discussed them builds confidence.

Many hospitals designate a core team for oncolytic therapy: a small group of pharmacists, nurses, and physicians who handle all such cases. This concentration of expertise ensures consistency and that lessons from one case inform the next. Over time, as OV therapy becomes more routine, training can expand to more staff, but initially keeping the team small can help maintain quality control.

Patient Education and Counselling

A critical component of OV implementation is educating the patient (and their family) about the therapy and safety measures. The idea of a "virus" as treatment can be confusing or intimidating, so it's important to explain in clear, reassuring terms. Pharmacists and nurses often handle this counseling in partnership with the physician.

Patients are told, for example: "This treatment uses a virus that's been modified to only attack cancer cells. It won't behave like a typical infection in your body; instead, it's there to break down the tumor and help your immune system recognize the cancer." Emphasizing that the virus has been engineered for safety (cannot replicate uncontrollably, etc.) can alleviate fears of getting sick from the virus [41,42].

Home Precautions are a big focus in counseling. The patient is given a printed handout detailing what to do when they go home:

- Keep all injection sites covered with the bandages provided. Typically, they should change the dress after 1 week (or sooner if it gets wet or loose) and continue covering until the site is completely healed. When changing the dressing, they should wear disposable gloves (the clinic often provides these) and place the used dressing and gloves into a plastic zip-lock bag, seal it, and throw it in the regular trash (or return it to the clinic if instructed).
- Maintain good hygiene: wash hands thoroughly after touching the treatment site or bandages. Avoid touching or scratching the injection area.
- Laundry that may have been contaminated (clothing or bedding with blood/pus from the injection site) should be washed separately from other family laundry, with hot water if possible.
- Limit close contact with others for the first few days, especially avoiding contact with infants, pregnant women, or anyone with a weakened immune system. This doesn't mean complete isolation – patients can be around others but should avoid activities like sexual intercourse (use a condom if they do engage in sex) or sharing personal items like towels during that week.
- If they have young children or pets at home, cover any treated area before holding them, and avoid allowing pets to lick or disturb the injection sites [43].

The patient is also educated on side effect management (as discussed earlier): they can use acetaminophen for fever, take it easy if they feel tired or flu-ish after treatment, and use pain relievers or ice packs for injection site discomfort. The care team provides a contact number for any questions or in case concerning symptoms arise (e.g., high fever not controlled with Tylenol, or any signs of allergic reaction, which are very rare with OVs). Finally, it's important to assess the patient's understanding. Nurses

often use "teach-back," asking the patient to repeat key instructions to ensure nothing was misunderstood. Involving a caregiver in this teaching (when possible) is also wise, because they can help the patient adhere to precautions and note any issues [44].

Overall, thorough patient education not only protects others but also makes the patient a partner in their own care. When patients understand the therapy and the reasons behind each precaution, they are generally very cooperative and even appreciative of the proactive safety measures. Many patients find it empowering to know their treatment is high-tech and that with a few simple steps they can safely undergo what once would only be available in a controlled lab setting [45].

Conclusion

The hospital implementation of oncolytic virus therapy requires diligent planning but is entirely feasible with a structured approach. Early experiences with agents like T-VEC have shown that even non-research hospitals can safely handle and administer oncolytic viruses by adhering to well-defined protocols. The cornerstones of safety are: following BSL-2 biosafety practices, maintaining the cold chain and integrity of the live product, using proper PPE and engineering controls during preparation and administration, and thoroughly educating everyone involved – from staff to the patient and family – about their role in containment.

Oncology pharmacists have played a pivotal role, often leading the development of SOPs and serving as the hub of coordination between departments. Nursing and medical staff have adapted procedures to incorporate steps like dressing application and contact precautions seamlessly into patient care. Infection control and environmental services involvement ensures that the hospital environment remains safe and decontaminated [46].

By treating an oncolytic virus similarly to a hazardous drug and an infectious agent, hospitals create a dual layer of safety that has proven effective. To date, there have been no reports of unintended harm to healthcare workers or the public from approved oncolytic virotherapies, indicating that the precautions are working.

Importantly, these efforts open the door for patients to receive cutting-edge treatments in their own communities. Instead of having to travel to specialized centers, patients can get OV therapy at local hospitals that have prepared accordingly. This broader accessibility could be life-changing for patients with tumors that are good candidates for virotherapy.

In conclusion, integrating oncolytic viruses into clinical practice exemplifies how innovation in treatment must be matched by innovation in operations. Through proactive planning, comprehensive training, and strict adherence to safety protocols, hospitals can offer oncolytic virus therapies while protecting patients, staff, and families. The early adopters have demonstrated it can be done safely and smoothly. As more OVs become available, the groundwork laid now – in protocols, experience, and confidence – will ensure that this exciting modality becomes a routine part of cancer care, delivered with the same level of safety and professionalism as any other therapy in the oncology arsenal.

Acknowledgements

We sincerely acknowledge the R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, offers a conducive academic environment, advanced research facilities, and continuous support throughout the course of this work.

Conflict of Interest

The authors declare that they have no competing interests in relation to this work.

Funding

Nil

Inform Consent and Ethical Statement

Not Applicable

Author Contribution

All authors are Contributed Equally.

References

1. Larson C, Oronsky B, Varner G, Caroen S, Burbano E, Insel E, et al. A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs). Oncoimmunology [Internet]. 2018 Jul 23 [cited 2025 Sep 7];7(9):e1478648. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140583/
2. Nguyen HM, Sah N, Humphrey MRM, Rabkin SD, Saha D. Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus. J Vis Exp. 2021 May 13;(171).
3. Chen L, Zuo M, Zhou Q, Wang Y. Oncolytic virotherapy in cancer treatment: challenges and optimization prospects. Front Immunol [Internet]. 2023 Dec 15 [cited 2025 Sep 7];14. Available from: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1308890/full
4. Mestiri S, Sami A, Sah N, El-Ella DMA, Khatoon S, Shafique K, et al. Cellular plasticity and non-small cell lung cancer: role of T and NK cell immune evasion and acquisition of resistance to immunotherapies. Cancer Metastasis Rev. 2025 Jan 25;44(1):27.
5. Acharya G, Mani C, Sah N, Saamarthy K, Young R, Reedy MB, et al. CHK1 inhibitor induced PARylation by targeting PARG causes excessive replication and metabolic stress and overcomes chemoresistance in ovarian cancer. Cell Death Discov. 2024 Jun 11;10(1):278.

6. McBride A, Valgus J, Parsad S, Sommermann EM, Nunan R. Pharmacy Operationalization of the Intralesional Oncolytic Immunotherapy Talimogene Laherparepvec. Hosp Pharm [Internet]. 2018 Oct [cited 2025 Sep 7];53(5):296–302. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6130110/
7. Wang H, Borlongan M, Hemminki A, Basnet S, Sah N, Kaufman HL, et al. Viral Vectors Expressing Interleukin 2 for Cancer Immunotherapy. Hum Gene Ther. 2023 Sep;34(17–18):878–95.
8. Robilotti E, Zeitouni NC, Orloff M. Biosafety and biohazard considerations of HSV-1–based oncolytic viral immunotherapy. Front Mol Biosci [Internet]. 2023 Sep 12 [cited 2025 Sep 8];10:1178382. Available from: https://www.frontiersin.org/articles/10.3389/fmolb.2023.1178382/full
9. Connor TH. Hazardous Anticancer Drugs in Health Care: Environmental Exposure Assessment. Annals of the New York Academy of Sciences [Internet]. 2006 Sep [cited 2025 Sep 8];1076(1):615–23. Available from: https://nyaspubs.onlinelibrary.wiley.com/doi/10.1196/annals.1371.021
10. Robilotti E, Zeitouni NC, Orloff M. Biosafety and biohazard considerations of HSV-1–based oncolytic viral immunotherapy. Front Mol Biosci [Internet]. 2023 Sep 12 [cited 2025 Sep 8];10:1178382. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546393/
11. Nitrile-Xtra P, Underguard P, Nitrile-Xtra S. BE IN COMPLIANCE WITH HALYARD* CHEMO GEAR.
12. Casanova L, Alfano-Sobsey E, Rutala WA, Weber DJ, Sobsey M. Virus Transfer from Personal Protective Equipment to Healthcare Employees' Skin and Clothing. Emerg Infect Dis [Internet]. 2008 Aug [cited 2025 Sep 8];14(8):1291–3. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2600382/
13. Varghese J, Sah N, Ramaiah B. PDG50 Obstacles in the IV to ORAL Antibiotic Shift for Eligible Patients at a Tertiary Care Hospital. Value in Health [Internet]. 2020 Dec 1 [cited 2025 Sep 8];23:S527. Available from: https://www.valueinhealthjournal.com/article/S1098-3015(20)32989-2/fulltext
14. CDC. Healthcare-Associated Infections (HAIs). 2024 [cited 2025 Sep 8]. Basic Infection Control and Prevention Plan for Outpatient Oncology Settings. Available from: https://www.cdc.gov/healthcare-associated-infections/hcp/prevention-healthcare/infection-control-outpatient-oncology.html
15. Huddleston C, Mani C, Sah N, Courtney E, Reese K, Stroever S, et al. Evaluating Efficacy of Cervical HPV-HR DNA Testing as Alternative to PET/CT Imaging for Posttreatment Cancer Surveillance: Retrospective Proof-of-Concept Study. Cancer Epidemiol Biomarkers Prev. 2025 Aug 1;34(8):1264–8.
16. Okechukwu CC, Ma X, Sah N, Mani C, Palle K, Gmeiner WH. Enhanced Therapeutic Efficacy of the Nanoscale Fluoropyrimidine Polymer CF10 in a Rat Colorectal Cancer Liver Metastasis Model. Cancers (Basel). 2024 Mar 30;16(7):1360.
17. Schumacher TJ, Sah N, Palle K, Rumbley J, Mereddy VR. Synthesis and biological evaluation of benzofuran piperazine derivatives as potential anticancer agents. Bioorg Med Chem Lett. 2023 Sep 1;93:129425.
18. Robilotti EV, Kumar A, Glickman MS, Kamboj M. Viral oncolytic immunotherapy in the war on cancer: Infection control considerations. Infect Control Hosp Epidemiol [Internet]. 2019 Mar [cited 2025 Sep 8];40(3):350–4. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859840/
19. Sah N, Ramaiah B, Koneri R. Sulfasalazine-induced drug rash with eosinophilia and systemic symptoms syndrome in a seronegative spondyloarthritis patient: A Case report. Indian J Pharmacol. 2021;53(5):391–3.
20. Robilotti EV, Kumar A, Glickman MS, Kamboj M. Viral oncolytic immunotherapy in the war on cancer: Infection control considerations. Infect Control Hosp Epidemiol [Internet]. 2019 Mar [cited 2025 Sep 8];40(3):350–4. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859840/
21. Kiser ML. Spill of agent OUTSIDE of a Biosafety Cabinet (BSC).
22. Needle-stick Guideline Treatment & Management: Approach Considerations, Prehospital Care, Emergency Department Care. 2025 Mar 28 [cited 2025 Sep 8]; Available from: https://emedicine.medscape.com/article/784812-treatment
23. Pan L, Liu X, Fan D, Qian Z, Sun X, Wu P, et al. Study of Oncolytic Virus Preservation and Formulation. Pharmaceuticals (Basel) [Internet]. 2023 Jun 5 [cited 2025 Sep 8];16(6):843. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302305/
24. Exploring Oncolytic Viruses in Melanoma: Pharmacist-Led Approaches for Safe Integration [Internet]. [cited 2025 Sep 8]. Available from: https://www.pharmacytimes.org/courses/exploring-oncolytic-viruses-in-melanoma-pharmacist-led-approaches-for-safe-integration-8rew
25. Sah N, Ramaiah B, Koneri R. The Pharmacist Role in Clinical Audit at an Indian Accredited Hospital: An Interventional Study. IJOPP [Internet]. 2019 Jun 1

[cited 2025 Sep 8];12(2):117–25. Available from: http://ijopp.org/article/662

26. Disposing of Medical Waste Properly [Internet]. 2025 [cited 2025 Sep 8]. Available from: https://www.actenviro.com/medical-waste-disposal-guide/
27. Research C for DE and. FDA. FDA; 2023 [cited 2025 Sep 8]. Safely Using Sharps (Needles and Syringes) at Home, at Work and on Travel. Available from: https://www.fda.gov/medical-devices/consumer-products/safely-using-sharps-needles-and-syringes-home-work-and-travel
28. Sheth RA, Wehrenberg-Klee E, Patel SP, Brock KK, Fotiadis N, de Baère T. Intratumoral Injection of Immunotherapeutics: State of the Art and Future Directions. Radiology [Internet]. 2024 Jul [cited 2025 Sep 8];312(1):e232654. Available from: https://pubs.rsna.org/doi/full/10.1148/radiol.232654
29. Huddleston C, Fakhreddine AB, Stroever S, Young R, Sah N, Palle K, et al. Abstract 1305: Comparison of HPV-DNA testing to PET-CT imaging as prognostic test following definitive treatment for cervical cancer: A retrospective proof-of-concept study. Cancer Res [Internet]. 2024 Mar 22 [cited 2025 Sep 8];84(6_Supplement):1305. Available from: https://doi.org/10.1158/1538-7445.AM2024-1305
30. Huddleston C, Mani C, Sah N, Courtney E, Reese K, Stroever S, et al. Evaluating Efficacy of Cervical HPV-HR DNA Testing as Alternative to PET/CT Imaging for Posttreatment Cancer Surveillance: Retrospective Proof-of-Concept Study. Cancer Epidemiol Biomarkers Prev [Internet]. 2025 Aug 1 [cited 2025 Sep 8];34(8):1264–8. Available from: https://doi.org/10.1158/1055-9965.EPI-24-1828
31. Guan X, Yan H, Zhang J, Li Y, Zhou Y. Risk factors of infection of totally implantable venous access port: A retrospective study. J Vasc Access [Internet]. 2023 Nov 1 [cited 2025 Sep 8];24(6):1340–8. Available from: https://doi.org/10.1177/11297298221085230
32. Oncolytic Virus Therapy: What It Is, How It Works & Risks [Internet]. 2024 [cited 2025 Sep 8]. Available from: https://www.cityofhope.org/tests-procedures-treatments/oncolytic-virus-therapy
33. Roestenberg M, Mo A, Kremsner PG, Yazdanbakhsh M. Controlled human infections: A report from the controlled human infection models workshop, Leiden University Medical Centre 4–6 May 2016. Vaccine [Internet]. 2017 Dec 18 [cited 2025 Sep 8];35(51):7070–6. Available from: https://www.sciencedirect.com/science/article/pii/S0264410X17315219
34. Sah N, Shaik AA, Acharya G, Dunna M, Silwal A, Sharma S, et al. Receptor-Based Strategies for Overcoming Resistance in Cancer Therapy. Receptors [Internet]. 2024 Dec [cited 2025 Sep 8];3(4):425–43. Available from: https://www.mdpi.com/2813-2564/3/4/21
35. Sah N, Luna P, Mani C, Gmeiner W, Palle K. A Novel Fluoropyrimidine Drug to Treat Recalcitrant Colorectal Cancer. The Journal of Pharmacology and Experimental Therapeutics [Internet]. 2023 Jun 1 [cited 2025 Sep 8];385:441. Available from: https://www.sciencedirect.com/science/article/pii/S0022356524168796
36. Spirito F, Nocini R, Mori G, Albanese M, Georgakopoulou EA, Sivaramakrishnan G, et al. The Potential of Oncolytic Virotherapy in the Treatment of Head and Neck Cancer: A Comprehensive Review. Int J Mol Sci [Internet]. 2024 Dec 3 [cited 2025 Sep 8];25(23):12990. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11641702/
37. Sands JM, Champiat S, Hummel HD, Paulson KG, Borghaei H, Alvarez JB, et al. Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3–targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer. Cancer [Internet]. 2025 [cited 2025 Sep 8];131(3):e35738. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.35738
38. Mohammed HS, Mohammad ZAE lateef, Azer SZ, Khallaf SM. Impact of In- Service Training Program on Nurses' Performance for Minimizing Chemotherapy Extravasation. Asian Pac J Cancer Prev [Internet]. 2023 [cited 2025 Sep 8];24(10):3537–42. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10770676/
39. Harrington KJ, Michielin O, Malvehy J, Pezzani Grüter I, Grove L, Frauchiger AL, et al. A practical guide to the handling and administration of talimogene laherparepvec in Europe. Onco Targets Ther. 2017;10:3867–80.
40. Richardson B, Anderson A, Lakey K, Hickham L, Sah N, Mani C, et al. Assessing the Need and Implementation of Health Literacy Testing for New Gynecologic Oncology Patients in West Texas: A Prospective Pilot Study. Texas Public Health Journal [Internet]. 2025 Jan 1 [cited 2025 Sep 8];77(1):18–24. Available from: https://research.ebsco.com/linkprocessor/plink?id=bd8e0ed4-6f24-37d8-b569-cdff4cff5da9
41. Mason TM. Personal protective equipment for antineoplastic safety. Nursing [Internet]. 2023 Aug [cited 2025 Sep 8];53(8):42–5. Available from: https://journals.lww.com/10.1097/01.NURSE.0000942856.87753.8a
42. Sah N, Ramaiah B, Abdulla, Gupta AK, Thomas SM. Noncompliance with Prescription-Writing Guidelines in an OutpatientDepartment of a Tertiary Care Hospital: A Prospective, Observational Study.

rjps [Internet]. 2020 [cited 2025 Sep 8];10(1). Available from: https://rjps.journalgrid.com/view/article/rjps/284

43. Terrie YC, Pharm BS, RPh, Pharmacist C. The Impact of Patient Education in Oncology/Hematology Care: Empowering Patients in Their Battle Against Cancer. First Report Managed Care [Internet]. 2020 Aug 31 [cited 2025 Sep 8];17(7). Available from: https://www.hmpgloballearningnetwork.com/site/frmc/articles/impact-patient-education-oncologyhematology-care-empowering-patients-their-battle-against
44. Larson C, Oronsky B, Varner G, Caroen S, Burbano E, Insel E, et al. A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs). Oncoimmunology [Internet]. 2018 Jul 23 [cited 2025 Sep 8];7(9):e1478648. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140583/
45. Stewart P. Fostering Partnerships With Patients Is Essential for Ensuring High-Quality Cancer Care. 2023 Jul 26 [cited 2025 Sep 8]; Available from: https://theoncologynurse.com/articles/fostering-partnerships-with-patients-is-essential-for-ensuring-high-quality-cancer-care
46. Varghese J, Sah N, Thomas SM, Jose JC, Ramaiah B, Koneri R. PDG6 Clinical Evaluation of Skin and Soft Tissue Infections in Inpatient Versus Outpatient Setting at a Tertiary Care Hospital - a Prospective Study. Value in Health [Internet]. 2020 Dec 1 [cited 2025 Sep 8];23:S521–2. Available from: https://www.valueinhealthjournal.com/article/S1098-3015(20)32945-4/fulltext